Get visibility into your progress toward diversity goals when patients are in the enrollment funnel
To generate the most relevant data on the efficacy of a therapy or medical device, clinical trial participants need to represent the diverse population that will eventually use it. Per FDA draft guidance, sponsors will be required to create and implement Race and Ethnicity Diversity Plans for phase 3 studies, and other pivotal studies, of new therapies.
As global diversity measures continue to take shape, it’s critical that sponsors ensure their clinical trial technology has diversity reporting capabilities to track progress toward these initiatives – and to inform early interventions as needed.
Sponsors who use StudyTeam Diversity Reports access insights about:
All of these insights are categorized by race and ethnicity. This enables you to pinpoint diversity challenges earlier in the enrollment funnel, whether specific I/E criteria are disproportionately affecting certain populations or whether specific patient populations are declining to participate in your trial for reasons that could be addressed.
Don’t wait to receive insights about patient representation until after informed consent, enrollment, and randomization. The sooner you get insights with StudyTeam, the sooner you can course correct.
Get specific insights from your sites’ de-identified pre-screening data. Note patterns in I/E criteria failures across underrepresented populations, and reasons populations decline to participate.
Whether you’re implementing an FDA Race and Ethnicity Diversity Plan or following another recommendation, start tracking progress toward your goals at the very beginning of your enrollment funnel.
StudyTeam, our cloud-based patient enrollment management platform, enables sites and sponsors to collaborate more effectively on clinical trials. The goal? Accelerating the development of new and life-saving therapies.
With StudyTeam, it's easier for sites to log and share the diversity data sponsors need to meet enrollment goals.